ACE-031 1mg/vial Neutralize Myostatin And Activate Muscle Growth Potential

ACE-031 1mg/vial core introduction

Activin receptor IIB fusion protein | Muscle growth regulator 1mg/vial

Generic name : ACE-031 (ActRIIB-Fc)

English name : ACE-031

Protein structure : A recombinant fusion protein, formed by the fusion of the activin receptor IIB extracellular domain and a human IgG1 Fc fragment.

Molecular weight : Approximately 100-120 kDa (after glycosylation)

Purity : ≥90% (SDS-PAGE/HPLC)

Content : 1mg/bottle

Appearance : White or off-white lyophilized powder

Storage : Freeze at -80℃, protect from light, and store in a dry place.

Usage and Storage Guide

ACE-031 (activin receptor IIB-Fc fusion protein):

ACE-031 is a recombinant fusion protein formed by fusing the extracellular ligand-binding domain of the activin receptor IIB with the Fc fragment of human immunoglobulin G1 (IgG1). As a soluble decoy receptor, it binds with high affinity to and neutralizes negative regulators of muscle growth (such as myostatin/GDF-8, activin, etc.), thereby blocking their downstream signaling pathways. In experimental models, this blocking effect leads to a significant increase in skeletal muscle mass. Unlike direct injection of growth factors, ACE-031 exerts its effects by relieving endogenous growth-inhibiting signals, providing a powerful tool for studying the molecular mechanisms of muscle hypertrophy, muscle atrophy diseases (such as Duchenne muscular dystrophy and cachexia), and muscle metabolism.

Due to its unique mechanism of promoting muscle growth by relieving endogenous inhibitory signals, ACE-031 has attracted significant attention from researchers in muscle biology, neuromuscular diseases, cachexia (such as cancer cachexia and sarcopenia), and regenerative medicine. Compared to traditional anabolic steroids, its protein-protein interaction-based mechanism may offer a different spectrum of action, making it an important research tool in studying the precise regulation of muscle homeostasis, evaluating novel anti-muscle atrophy therapies, and exploring animal models of muscle interactions with other organs (such as bone and fat).

ACE-031 Applications:

As a soluble decoy receptor, it is used in in vitro and in vivo models to bind with high affinity and neutralize TGF-β superfamily members such as myostatin (GDF-8) and activin, thereby studying the effects of blocking this signaling pathway on myoblast differentiation, skeletal muscle mass and function, and systemic metabolism. It is primarily used to explore treatment strategies for muscular atrophy diseases, regenerative repair after muscle injury, and the relationship between muscle and energy metabolism.

It is widely used in animal models of Duchenne muscular dystrophy, cancer cachexia models, studies of age-related sarcopenia, and exploration of the mechanisms of muscle regeneration and hypertrophy. Its standardized recombinant protein form provides a key experimental reagent for evaluating the therapeutic potential of targeting the ActRIIB signaling pathway and understanding the muscle growth regulatory network under strictly controlled experimental conditions.

Usage and Storage Methods

1. Reconstitution and preparation :

Recommended solvent :

Preferred solvent : sterile water for injection or sterile phosphate-buffered saline (PBS) at pH 6.0-7.2 . Acidic solvents are strictly prohibited.

Key carrier : It is strongly recommended to add a carrier protein to the reconstitution and all dilution solutions . Sterile PBS containing 0.1%-1% bovine serum albumin (BSA) or 0.1% HSA is recommended to prevent protein adsorption and aggregation.

Working solution dilution : Dilute with sterile PBS containing carrier proteins .

Absolutely prohibited : It is strictly forbidden to use distilled water, deionized water, or protein-free buffer solutions to directly prepare high-concentration stock solutions . Avoid vortexing, violent shaking, or repeated blowing and agitation.

Standard preparation procedure :

Solvent preparation :

Use PBS (pH 7.0-7.2) that has been sterile filtered through a 0.22 μm filter membrane or sterile water for injection.

It is recommended to add BSA or HSA to the solvent to a final concentration of 0.1%-1%.

Pre-cool the solvent on ice or use fresh solvent at room temperature.

Reconstitution procedure :

Perform the procedure in a clean environment. Add 1.0 mL of the recommended solvent to a 1 mg vial.

Allow the solvent to flow slowly down the bottle wall , and absolutely avoid direct impact on the freeze-dried cake.

Place the vial on a table and tilt and rotate it very slowly to allow the solvent to soak all the powder. Let it stand for 10-15 minutes to dissolve naturally.

Do not vortex, vibrate, or shake violently. Gently invert to mix.

Final concentration: 1 mg/mL (approximately 8-12 μM, depending on the degree of glycosylation) stock solution.

Dispensing and dilution :

Immediately dispense into single doses of 5-20 μL using low-adsorption centrifuge tubes (such as silanized tubes).

If dilution is required, perform serial dilutions using PBS containing the carrier protein. Avoid large-scale dilutions in one step.

Clearly labeled: ACE-031, concentration, preparation date, batch number, storage temperature.

Working concentration reference :

In vitro cell experiments : The commonly used concentration range is 1 to 20 μg/mL (approximately 10 to 200 nM), which needs to be optimized according to cell type and experimental purpose.

Animal in vivo experiments : Dosage must be strictly determined according to published animal model literature . Common routes of administration are subcutaneous or intraperitoneal injection, with dosages typically in the mg/kg range. Preliminary experiments are mandatory .

Calculation example : To prepare a 10 μg/mL working solution, take 10 μL of the 1 mg/mL stock solution and add it to 990 μL of PBS containing 0.1% BSA.

Key points to note :

Handle with care : Handling must be extremely gentle to avoid creating foam, bubbles, or shearing forces that could denature the protein.

Carrier protein : It is essential to reconstitute and dilute the protein using a solution containing the carrier protein , as this is crucial to prevent the protein from adsorbing onto the container surface and aggregating.

Slow reconstitution : Allow the lyophilized powder to dissolve slowly and naturally in the solvent ; if necessary, the standing time can be extended.

Freeze-thaw cycle strictly prohibited : Repeated freeze-thaw cycles are strictly prohibited ; the solution must be dispensed in one go. The diluted working solution should be used as soon as possible.

Observe the condition : After reconstitution, the solution should be clear, colorless or pale yellow, and slightly viscous. The presence of cloudiness, flocculent matter, or particles indicates that the protein may have aggregated, and its usability should be carefully assessed.

2. Storage conditions :

Unreconstituted lyophilized powder :

Long-term storage : Deep freeze at -80℃ . Do not store at -20℃.

Shelf life : At -80℃, the recommended storage period is 12 months.

Strictly protect from light : Store in the original light-proof aluminum foil bag with a desiccant inside.

Reconstituted solution :

Immediate dispensing : Dispensing should be done immediately on ice after reconstitution .

Repackaging and freezing : After repackaging , store at -80℃ for a maximum of 1 month. Long-term storage is not recommended.

Working solution : Diluted working solution must not be stored . It should be kept on ice and used up on the same day.

Transportation conditions :

It must be transported under dry ice (-78℃) conditions.

The packaging must ensure that the product remains frozen throughout the entire process.

3. Stability and Processing Standards :

Physicochemical stability :

Stable in near-neutral pH (6.0–7.5) buffer solutions. Avoid extreme pH values.

It is extremely sensitive to mechanical stress (vortex, oscillation, bubbling) and repeated freeze-thaw cycles .

It is sensitive to surface adsorption, so a carrier protein and a low-adsorption container must be used.

Maintaining bioactivity :

Follow the principles of " gentle handling, carrier protection, slow reconstitution, deep freezing, and strict prohibition of freezing and thawing ".

Need anything, please contact us

Hot Tags: ace-031 1mg/vial neutralize myostatin and activate muscle growth potential, China ace-031 1mg/vial neutralize myostatin and activate muscle growth potential manufacturers, suppliers, factory, AOD9604 Ideal For Competition Prep Peak Weeks, ace 031 1mg, buy aod 9604 pills, peptide cjc ipamorelin, Alternative to GHRP 6, hgh ipamorelin